Brief: Actinium Pharmaceuticals Says ACTIMAB-A CLAG-M Phase 1 Trial Is Expected To Be Completed In Mid-2020
09/12/2019 11:28
Dec 9 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS HIGHLIGHTS 86% RESPONSE RATE AND
71%
MRD NEGATIVE RATE IN ACTIMAB-A CLAG-M COMBINATION TRIAL IN
PATIENTS WITH RELAPSED OR REFRACTORY AML AT ASH 2019 ANNUAL
MEETING
* ACTINIUM PHARMACEUTICALS INC - ACTIMAB-A CLAG-M PHASE 1
TRIAL IS
EXPECTED TO BE COMPLETED IN MID-2020
* ACTINIUM PHARMACEUTICALS - ADDITION OF ACTIMAB-A TO CLAG-M
APPEARS TO HAVE A CLINICALLY ACCEPTABLE SAFETY PROFILE WITH NO
PATIENT DEATHS REPORTED
Source text for Eikon: ID:nPn5lZTsva
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities